All In Biotech

Drug Trial Radar · NCT00535587

Testing Mestinon and Exercise in Fibromyalgia

Maximizing Exercise Effectiveness in Fibromyalgia

Last checked: Nov 19, 2026Latest source record: Apr 18, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Sep 2002

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Oregon Health and Science UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Nursing Research (NINR)
First posted
Sep 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial was to test the combined and independent effects of 6 months of exercise and Mestinon in people with fibromyalgia. Specifically, we wanted to determine if Mestinon helped people with fibromyalgia have an easier time exercising and if their symptoms improved by the end of the trial.

Conditions

  • Fibromyalgia

Interventions

  • ExerciseBehavioral

  • pyridostigmineDrug

  • PlaciboDrug

  • Attention ControlBehavioral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Levels of Growth Hormone Post ExerciseTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oregon Health & Science University

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.